What is the share price of Kilitch Drugs (India) Ltd (KILITCH) today?
The share price of KILITCH as on 13th June 2025 is ₹454.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kilitch Drugs (India) Ltd (KILITCH) share?
The past returns of Kilitch Drugs (India) Ltd (KILITCH) share are- Past 1 week: 2.58%
- Past 1 month: 8.34%
- Past 3 months: 44.47%
- Past 6 months: 40.04%
- Past 1 year: 36.00%
- Past 3 years: 184.06%
- Past 5 years: 293.51%
What are the peers or stocks similar to Kilitch Drugs (India) Ltd (KILITCH)?
The peers or stocks similar to Kilitch Drugs (India) Ltd (KILITCH) include:What is the market cap of Kilitch Drugs (India) Ltd (KILITCH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kilitch Drugs (India) Ltd (KILITCH) is ₹729.98 Cr as of 13th June 2025.What is the 52 week high and low of Kilitch Drugs (India) Ltd (KILITCH) share?
The 52-week high of Kilitch Drugs (India) Ltd (KILITCH) is ₹499 and the 52-week low is ₹299.95.What is the PE and PB ratio of Kilitch Drugs (India) Ltd (KILITCH) stock?
The P/E (price-to-earnings) ratio of Kilitch Drugs (India) Ltd (KILITCH) is 27.33. The P/B (price-to-book) ratio is 4.16.Which sector does Kilitch Drugs (India) Ltd (KILITCH) belong to?
Kilitch Drugs (India) Ltd (KILITCH) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kilitch Drugs (India) Ltd (KILITCH) shares?
You can directly buy Kilitch Drugs (India) Ltd (KILITCH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kilitch Drugs (India) Ltd
KILITCH Share Price
454.500.01% (-0.05)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KILITCH Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KILITCH Performance & Key Metrics
KILITCH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.73 | 4.16 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
KILITCH Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KILITCH Company Profile
Kilitch Drugs (India) Limited is engaged in the development and operations of pharmaceutical business. The Company's services range from manufacturing to marketing a host of formulations in solid, liquid and parenteral forms.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.38%
2.38%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
72.00
72.00
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
81.25
81.25
KILITCH Sentiment Analysis
KILITCH Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
KILITCH Stock Summary · June 2024
Kilitch Drugs India Limited is strategically positioned for growth, particularly in the Ethiopian market, where it holds a unique competitive advantage as the sole supplier of Cephalosporin. Despite facing challenges with declining standalone revenue in Q4 FY24, the company anticipates a robust year-on-year growth of 25%-30% for FY25, bolstered by significant government contracts and an expanding product portfolio. Operational enhancements, including a new manufacturing facility in Khopoli and increased capacity at the Mumbai plant, are expected to drive efficiency and revenue. The proactive approach to working capital management, coupled with a focus on regulatory compliance, underscores the company's commitment to sustaining stakeholder confidence and optimizing financial performance. Overall, the sentiment remains optimistic, reflecting confidence in future revenue generation and market expansion.
KILITCH Stock Growth Drivers
KILITCH Stock Growth Drivers
7Expansion of Manufacturing Capabilities
Kilitch Drugs India Limited has successfully expanded its manufacturing capabilities, including the establishment of a
Successful International Business Growth
The company has achieved significant growth in its international business, securing new product approvals and
KILITCH Stock Challenges
KILITCH Stock Challenges
3Decline in Q4 Financial Performance
In Q4 FY 2023-24, the company reported a decline in standalone total operating revenue, which
Mixed Annual Financial Results
For the full financial year 2023-24, while the company saw an increase in total operating
KILITCH Forecast
KILITCH Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
KILITCH
KILITCH
Income
Balance Sheet
Cash Flow
Annual Normal View
KILITCH Income Statement
KILITCH Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 29.79 | 53.89 | 86.49 | 57.45 | 71.19 | 117.14 | 142.52 | 158.85 | 209.48 | 209.48 | ||||||||||
Raw Materials | 10.50 | 26.44 | 48.35 | 29.82 | 36.22 | 65.48 | 74.53 | 79.08 | 166.85 | 167.23 | ||||||||||
| Power & Fuel Cost | 1.06 | 1.11 | 1.42 | 1.62 | 1.57 | 1.92 | 2.15 | 2.43 | ||||||||||||
| Employee Cost | 3.38 | 4.30 | 5.28 | 5.69 | 5.24 | 6.18 | 11.73 | 10.01 | ||||||||||||
| Selling & Administrative Expenses | 6.98 | 8.19 | 12.56 | 11.50 | 11.17 | 15.34 | 23.53 | 28.24 | ||||||||||||
| Operating & Other expenses | 7.27 | 5.28 | 7.60 | 4.28 | 9.01 | 14.81 | 9.93 | 10.35 | ||||||||||||
EBITDA | 0.60 | 8.57 | 11.28 | 4.54 | 7.98 | 13.41 | 20.65 | 28.74 | 42.63 | 42.25 | ||||||||||
| Depreciation/Amortization | 9.76 | 2.04 | 2.05 | 2.00 | 1.99 | 2.47 | 3.55 | 3.35 | 3.11 | 3.12 | ||||||||||
| PBIT | -9.16 | 6.53 | 9.23 | 2.54 | 5.99 | 10.94 | 17.10 | 25.39 | 39.52 | 39.13 | ||||||||||
| Interest & Other Items | 0.16 | 0.42 | 0.65 | 0.94 | 0.88 | 1.33 | 5.08 | 6.04 | 5.04 | 5.04 | ||||||||||
| PBT | -9.32 | 6.11 | 8.58 | 1.60 | 5.11 | 9.61 | 12.02 | 19.35 | 34.48 | 34.09 | ||||||||||
| Taxes & Other Items | -0.43 | 0.96 | 4.76 | 0.77 | 1.46 | 2.25 | 1.56 | 4.75 | 7.77 | 7.77 | ||||||||||
| Net Income | -8.89 | 5.15 | 3.82 | 0.83 | 3.65 | 7.36 | 10.46 | 14.60 | 26.71 | 26.32 | ||||||||||
| EPS | -6.72 | 3.82 | 2.63 | 0.54 | 2.36 | 4.74 | 6.71 | 9.22 | 16.60 | 16.37 | ||||||||||
| DPS | 0.00 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.13 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
KILITCH Company Updates
KILITCH Stock Peers
KILITCH Past Performance & Peer Comparison
KILITCH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kilitch Drugs (India) Ltd | 27.33 | 4.16 | — |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
KILITCH Stock Price Comparison
Compare KILITCH with any stock or ETFCompare KILITCH with any stock or ETF
KILITCH
KILITCH Holdings
KILITCH Shareholdings
KILITCH Promoter Holdings Trend
KILITCH Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KILITCH Institutional Holdings Trend
KILITCH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KILITCH Shareholding Pattern
KILITCH Shareholding Pattern
KILITCH Shareholding History
KILITCH Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing KILITCH stock
smallcases containing KILITCH stock
Looks like this stock is not in any smallcase yet.
KILITCH Events
KILITCH Events
KILITCH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KILITCH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KILITCH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KILITCH has not given any dividends in last 5 years
KILITCH Upcoming Dividends
KILITCH Upcoming Dividends
No upcoming dividends are available
KILITCH Past Dividends
KILITCH Past Dividends
Cash Dividend
Ex DateEx DateSep 20, 2019
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 20, 2019
Cash Dividend
Ex DateEx DateSep 18, 2018
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 18, 2018
Cash Dividend
Ex DateEx DateSep 24, 2012
Special
Special | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Sep 24, 2012
Cash Dividend
Ex DateEx DateAug 18, 2011
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Aug 18, 2011
Cash Dividend
Ex DateEx DateOct 14, 2010
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Oct 14, 2010
KILITCH Stock News & Opinions
KILITCH Stock News & Opinions
Articles & Videos
Earnings
Kilitch Drugs (India) consolidated net profit rises 189.69% in the March 2025 quarter
Net profit of Kilitch Drugs (India) rose 189.69% to Rs 10.40 crore in the quarter ended March 2025 as against Rs 3.59 crore during the previous quarter ended March 2024. Sales rose 36.61% to Rs 61.23 crore in the quarter ended March 2025 as against Rs 44.82 crore during the previous quarter ended March 2024. For the full year,net profit rose 82.88% to Rs 26.70 crore in the year ended March 2025 as against Rs 14.60 crore during the previous year ended March 2024. Sales rose 28.47% to Rs 198.32 crore in the year ended March 2025 as against Rs 154.37 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales61.2344.82 37 198.32154.37 28 OPM %23.8315.80 -15.8715.64 - PBDT14.696.23 136 37.5822.70 66 PBT13.845.30 161 34.4719.35 78 NP10.403.59 190 26.7014.60 83 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene board meeting
Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit rises 104.81% in the December 2024 quarter
Net profit of Kilitch Drugs (India) rose 104.81% to Rs 5.96 crore in the quarter ended December 2024 as against Rs 2.91 crore during the previous quarter ended December 2023. Sales rose 76.69% to Rs 56.17 crore in the quarter ended December 2024 as against Rs 31.79 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales56.1731.79 77 OPM %15.547.17 - PBDT9.063.64 149 PBT8.252.82 193 NP5.962.91 105 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene board meeting
Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit rises 81.86% in the September 2024 quarter
Net profit of Kilitch Drugs (India) rose 81.86% to Rs 8.62 crore in the quarter ended September 2024 as against Rs 4.74 crore during the previous quarter ended September 2023. Sales rose 15.22% to Rs 47.47 crore in the quarter ended September 2024 as against Rs 41.20 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales47.4741.20 15 OPM %12.8520.92 - PBDT10.957.60 44 PBT10.356.78 53 NP8.624.74 82 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) announces board meeting date
Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene AGM
Kilitch Drugs (India) announced that the 32th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit declines 60.12% in the June 2024 quarter
Net profit of Kilitch Drugs (India) declined 60.12% to Rs 1.34 crore in the quarter ended June 2024 as against Rs 3.36 crore during the previous quarter ended June 2023. Sales declined 8.51% to Rs 33.45 crore in the quarter ended June 2024 as against Rs 36.56 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.4536.56 -9 OPM %4.9616.90 - PBDT2.505.24 -52 PBT1.654.53 -64 NP1.343.36 -60 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to conduct board meeting
Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Krebs Biochemicals & Industries Ltd leads gainers in ‘B’ group
10 months agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 12.93%, vs industry avg of 9.02%
Over the last 5 years, market share stayed at 0.04%
Over the last 5 years, net income has grown at a yearly rate of 30.75%, vs industry avg of 15.29%